resulting from enhanced enteric uptake transport and/or decreased effux transport. (ii) Increased liver burden resulting from enhanced hepatic uptake transport and/or decreased efflux transport. (iii) Elevated toxic parent drug/metabolites due to enhanced metabolic activation and decreased metabolic detoxification. Severe drug toxicity resulting from the co‐occurrence of these multiple risk enhancing factors is the basis for the Multiple Determinant Hypothesis of idiosyncratic drug toxicity.
References
1 1 Honig S, Murray KA. Postsurgical pain: zomepirac sodium, propoxyphene/‐acetaminophen combination, and placebo. J Clin Pharmacol 1981; 21 (10):443–8.
2 2 Pircio AW, Buyniski JP, Roebel LE. Pharmacological effects of a combination of butorphanol and acetaminophen. Arch Int Pharmacodyn Ther 1978; 235(1):116–23.
3 3 Hopkinson JH, 3rd, Blatt G, Cooper M, Levin HM, Berry FN, Cohn H. Effective pain relief: comparative results with acetaminophen in a new dose formulation, propoxyphene napsylate‐acetaminophen combination, and placebo. Curr Ther Res Clin Exp 1976; 19(6):622–30.
4 4 Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: a double‐blind, crossover trial. Headache 1976; 15(4):282–7.
5 5 Walker JM. Value of an acetaminophen‐chlorzoxazone combination (parafon forte) in the treatment of acute musculoskeletal disorders. Curr Ther Res Clin Exp 1973; 15(5):248–52.
6 6 Steele RW, Young FS, Bass JW, Shirkey HC. Oral antipyretic therapy. Evaluation of aspirin‐acetaminophen combination. Am J Dis Child 1972; 123(3):204–6.
7 7 Cameron JS, Specht PG, Wendt GR. Effects of placebo and an acetaminophen‐salicylamide combination on moods, emotions, and motivations. J Psychol 1967; 67(2):257–62.
8 8 Lee WM. The case for limiting acetaminophen‐related deaths: smaller doses and unbundling the opioid‐acetaminophen compounds. Clin Pharmacol Ther 2010; 88(3):289–92.
9 9 Robinson AE, Sattar H, McDowall RD, Holder AT, Powell R. Forensic toxicology of some deaths associated with the combined use of propoxyphene and acetaminophen (paracetamol). J Forensic Sci 1977; 22(4):708–17.
10 10 Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity‐‐where do we go from here? Expert Opin Drug Saf 2007; 6(4):341–55.
11 11 Bailey BO. Acetaminophen hepatotoxicity and overdose. Am Fam Physician 1980; 22(1):83–7.
12 12 Fercovic A, Serra I, Serra L. Acetaminophen hepatotoxicity in an alcohol addicted student. Case report. Rev Med Chil 1999; 127(2):202–5.
13 13 Himmelstein DU, Woolhandler SJ, Adler RD. Elevated SGOT/SGPT ratio in alcoholic patients with acetaminophen hepatotoxicity. Am J Gastroenterol 1984; 79(9):718–20.
14 14 Johnson MW, Friedman PA, Mitch WE. Alcoholism, nonprescription drug and hepatotoxicity. The risk from unknown acetaminophen ingestion. Am J Gastroenterol 1981; 76(6):530–3.
15 15 Johnston SC, Pelletier LL, Jr. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Medicine (Baltimore). 1997; 76(3):185–91.
16 16 McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA 1980; 244(3):251–3.
17 17 Poulsen HE, Lerche A, Pedersen NT. Potentiated hepatotoxicity from concurrent administration of acetaminophen and allyl alcohol to rats. Biochem Pharmacol 1985; 34(6):727–31.
18 18 Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen‐induced hepatotoxicity. Hepatology 2002; 35(4):876–82.
19 19 Wootton FT, Lee WM. Acetaminophen hepatotoxicity in the alcoholic. South Med J 1990; 83(9):1047–9.
20 20 Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22(3):767–73.
21 21 Chomchai S, Chomchai C, Anusornsuwan T. Acetaminophen psi parameter: a useful tool to quantify hepatotoxicity risk in acute acetaminophen overdose. Clin Toxicol (Phila) 2011; 49(7):664–7.
22 22 Chomchai S, Lawattanatrakul N, Chomchai C. Acetaminophen Psi Nomogram: a sensitive and specific clinical tool to predict hepatotoxicity secondary to acute acetaminophen overdose. J Med Assoc Thai 2014; 97(2):165–72.
23 23 Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug‐induced hepatotoxicity‐‐two villains or one? J Pharmacol Exp Ther 2010; 332(3):692–7.
24 24 Proctor WR, Chakraborty M, Fullerton AM, Korrapati MC, Ryan PM, Semple K, et al. Thymic stromal lymphopoietin and interleukin‐4 mediate the pathogenesis of halothane‐induced liver injury in mice. Hepatology 2014; 60(5):1741–52.
25 25 Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 2009; 39(1):11–21.
26 26 Takahashi T, Lasker JM, Rosman AS, Lieber CS. Induction of cytochrome P‐4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA. Hepatology 1993; 17(2):236–45.
27 27 Badger TM, Ronis MJ, Ingelman‐Sundberg M, Hakkak R. Pulsatile blood alcohol and CYP2E1 induction during chronic alcohol infusions in rats. Alcohol 1993; 10(6):453–7.
28 28 Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P‐4502E1 genotypes. Alcohol Clin Exp Res 1996; 20 (1 Suppl):25A–8A.
29 29 Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, et al. Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 2000; 67(6):591–9.
30 30 Moss M, Guidot DM, Wong‐Lambertina M, Ten Hoor T, Perez RL, Brown LA. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Am J Respir Crit Care Med 2000; 161 (2 Pt 1):414–9.
31 31 Kostrubsky VE, Szakacs JG, Jeffery EH, Wood SG, Bement WJ, Wrighton SA, et al. Role of CYP3A in ethanol‐mediated increases in acetaminophen hepatotoxicity. Toxicol Appl Pharmacol 1997; 143(2):315–23.
32 32 Liang Y, Yeligar SM, Brown LA. Chronic‐alcohol‐abuse‐induced oxidative stress in the development of acute respiratory distress syndrome. Sci World J 2012; 2012:740308.
33 33 Koenderink JB, van den Heuvel J, Bilos A, Vredenburg G, Vermeulen NPE, Russel FGM. Human multidrug resistance protein 4 (MRP4) is a cellular efflux transporter for paracetamol glutathione and cysteine conjugates. Arch Toxicol 2020, 94, 3027–3032.
34 34 Barnes SN, Aleksunes LM, Augustine L, Scheffer GL, Goedken MJ, Jakowski AB, et al. Induction of hepatobiliary efflux transporters in acetaminophen‐induced acute liver failure cases. Drug Metab Dispos 2007; 35 (10):1963–9.
35 35 Ghanem CI, Gomez PC, Arana MC, Perassolo M, Ruiz ML, Villanueva SS, et al. Effect of acetaminophen on expression and activity of rat liver multidrug resistance‐associated protein 2 and P‐glycoprotein. Biochem Pharmacol 2004; 68(4):791–8.
36 36 Lima RA, Candido EB, de Melo FP, Piedade JB, Vidigal PV, Silva LM, et al. Gene expression profile of ABC transporters and cytotoxic effect of ibuprofen and acetaminophen in an epithelial ovarian cancer cell line in vitro. Rev Bras Ginecol Obstet 2015; 37(6):283–90.
37 37
